Brandywine Realty Trust

BDN · NYSE

$2.68+$0.08 (+3.08%)TodayMarket closed · Oct 20, 7:54 PM ET

Prev close $2.60

BDN analyst rating

HoldConsensus of 4 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold3
Underperform1
Sell0

12-month price target · 4 analysts

Average $3.06 (+14.2% upside)

Low: $2.53
Now: $2.68
High: $3.67

Upgrades and downgrades

The latest rating actions, newest first

BDN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Apr 28, 2026	Maintains	Hold	$3.50 → $3.00	45%
Keybanc	Dec 4, 2025	Downgrade	Overweight → Sector Weight	—	46%
JP Morgan	Nov 24, 2025	Downgrade	Neutral → Underweight	—	58%
Evercore ISI Group	Nov 14, 2025	Maintains	In-Line	$5.00 → $4.00	45%

The case for and against

Updated Feb 9, 2026

Bull case

Brandywine Realty Trust operates a diverse portfolio of properties across various segments, which positions the company favorably within the real estate sector. The current outlook suggests that the stock may benefit significantly from falling long-term interest rates, enhancing the potential for higher yields from development projects and improved refinancing rates. Additionally, healthy office demand in the CBD Philadelphia portfolio, coupled with the stabilization of active development projects, is expected to contribute positively to earnings in 2026.

Bear case

Brandywine Realty Trust is facing a challenging financial outlook, as it is projected to experience below-average earnings growth over the next three to five years, which raises concerns regarding its future profitability. Additionally, the company has been assigned unattractive Funds From Operations (FFO) and Funds Available for Distribution (FAD) Price-to-Earnings Growth (PEG) ratios, indicating limited potential for value appreciation in the stock. Furthermore, Brandywine's elevated financial leverage and concerns over the sustainability of its dividend payments exacerbate the negative outlook, coupled with weakening fundamentals in the life sciences sector, which could hinder new developments and leasing activities.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.